Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia - art. no. 173

Stein, AM and Martinelli, G and Hughes, TP and Mueller, MC and Beppu, L and Gottardi, E and Branford, S and Soverini, S and Woodman, RC and Hochhaus, A and Kim, DW and Saglio, G and Radich, JP (2013) Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia - art. no. 173. BMC CANCER. 173-.

Item Type: Article
Additional Information: pubid: 190 nvp_institute: NIBR contributor_address: Novartis Inst BioMed Res Inc, Cambridge, MA 02139 USA andrew.stein@novartis.com; Univ Bologna, Dept Hematol & Oncol Sci L&A Seragnoli, Bologna, Italy ; Royal Adelaide Hosp, Ctr Canc Biol SA Pathol, Adelaide, SA 5000, Australia ; Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany ; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA ; Univ Turin, Orbassano, Italy ; Nova Pharmaceut Corp, E Hanover, NJ USA ; Univ Klinikum Jena, Jena, Germany ; Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea ; Novartis Inst BioMed Res Inc, Cambridge, MA 02139 USA; Stein, A M; Novartis Inst BioMed Res Inc, 45 Sidney St, Cambridge, MA 02139 USA
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/22011

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.